Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Johnson & Johnson Pharmaceutical Research & Develo
Abstracts on elderly patients with acute myeloid leukemia presented at conference
January 9th, 2005
Data on tipifarnib (R115777), a compound under investigation by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., for the treatment of elderly patients with newly diagnosed poor-risk acute myeloid leukemia (AML), were presented at the 46th annual meeting of the American Society of Hematology (ASH). AML is a rapidly progressing form of leukemia, which, in elderly patients, often results in death within a few months of diagnosis. Although the number of cases of AML is difficult to track on a global scale, based on available information, it is estimated that more than 60,000 new cases will be diagnosed worldwide in 2004. This includes nearly 12,000 new cases...
Source: Aging & Elder Health Week (2005-01-09)
|
